GlassScriptPhysician profile
Mary Spivey
NPI 1073839981
$937.94
in general payments reported to CMS, 2019-2025
23 companies · $668 in 2025
The $668 reported for 2025 was more than what 83% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $37.01 · 2024: $233 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.17 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $163.38 | 2024-2025 | Rexulti |
| Abbvie INC. | $70.94 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.30 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.07 | 2025 | Trintellix |
| Exact Sciences Corporation | $45.73 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $33.63 | 2025 | Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.18 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $26.97 | 2024-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $26.87 | 2024 | |
| Alexion Pharmaceuticals, INC. | $25.96 | 2024 | Strensiq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.58 | 2025 | Caplyta |
| Resmed Corp | $22.68 | 2025 | |
| Pfizer INC. | $22.41 | 2025 | |
| Amgen INC. | $22.01 | 2025 | Evenity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $21.42 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $18.14 | 2025 | |
| Esperion Therapeutics, INC. | $17.82 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $17.62 | 2023 | Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $17.33 | 2025 | Symbravo |
| Boston Scientific Corporation | $15.97 | 2025 | Watchman Access System |
| Ascensia Diabetes Care US INC. | $15.59 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.17 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Spivey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.